Additional Study Information: The purpose of this study is to test the safety of the study drug, E-602, at different dose levels both alone (monotherapy) and in combination with Cemiplimab (also known as Libtayo). Cemiplimab is FDA-approved for the treatment of some cancers, but not all of the cancers in this study. E-602 has not been approved by the United States Food and Drug Administration (FDA). This study is the first time that E-602 will be administered to participants. The study will also inform on what effects, both good and bad, E-602 alone and in combination with Cemiplimab have on participants with advanced cancer. Cancers include: breast cancer, colon and rectal cancer, esophageal cancer, head and neck/oral cancer, lung cancer, melanoma, pancreatic cancer, and ovarian cancer.